Photo of Anat O. Stemmer-Rachamimov, MD

Anat O. Stemmer-Rachamimov, MD

  • Associate Pathologist, Massachusetts General Hospital
  • Associate Professor in Pathology, Harvard Medical School


Accepting New Patients

E-mail me Visit my website


Dr. Stemmer-Rachamimov is an attending pathologist on the Neuropathology and Autopsy services of Pathology, and is a member of the diagnostic staff of the Cogan Laboratory of Ophthalmic Pathology at Massachusetts Eye and Ear Infirmary.



Centers & Specialties

Cancer Center

  • Neuro-Oncology (Brain)
Clinical Interests
  • Neuropathology
  • Autopsy Pathology
  • Frozen Section Pathology
  • Molecular pathology
  • Ophthalmic pathology
Medical Education
  • MD, University of Milan
  • Residency, Memorial Hospital Health Science Centre, St. John's|Residency, University Hospital
  • Fellowship, Massachusetts General Hospital
Board Certifications
  • Anatomic Pathology
  • Neuropathology
  • Boston: Massachusetts General Hospital
Insurances Accepted
  • Aetna Health Inc.
  • Beech Street
  • Blue Cross Blue Shield - Blue Care 65
  • Blue Cross Blue Shield - Indemnity
  • Blue Cross Blue Shield - Managed Care
  • Blue Cross Blue Shield - Partners Plus
  • Centene/Celticare
  • Cigna (PAL #'s)
  • Fallon Community HealthCare
  • Great-West Healthcare (formally One Health Plan)
  • Harvard Pilgrim Health Plan - ACD
  • Harvard Pilgrim Health Plan - PBO
  • Health Care Value Management (HCVM)
  • Humana/Choice Care PPO
  • Medicaid
  • Medicare
  • Medicare - ACD
  • Neighborhood Health Plan - ACD
  • Neighborhood Health Plan - PBO
  • OSW - Maine
  • OSW - New Hampshire
  • OSW - Rhode Island
  • Private Health Care Systems (PHCS)
  • Railroad Medicare
  • Railroad Medicare - ACD
  • Senior Whole Health
  • TriCare
  • Tufts Health Plan
  • Unicare
  • United Healthcare (non-HMO) - ACD
  • United Healthcare (non-HMO) - PBO
Patient Age Group

Edit Profile


Anat Stemmer-Rachamimov, MD, is a faculty member of the C. S. Kubik Laboratory for Neuropathology providing diagnostic services, instruction to trainees on the Neuropathology service through didactic teaching sessions and routine sign-out procedures. She is the co-director of the DFHCC Specialized Histopathology Services Core, co-director of the Neuro Oncology Tissue Repository and the director of the Automated Biomarker Laboratory.

Her conference activities include weekly or monthly conferences with Pathology, Neurology and Neuro-Oncology. She has particular interest in tumor pathology and the weekly consensus review sessions in which all primary brain tumors are discussed, along with cases of complexity or particular interest. This session allows the neuropathology staff to maintain a consistent set of diagnostic criteria and terminology.

She is one of four neuropathologists that diagnose approximately 700 in-house surgical neuropathology cases, and 500 consultation cases per year. In a given year, over 900 intra-operative diagnostic consultations are processed.
Her research interests focus on identifying the underlying molecular changes in the lesions and malformations associated with hereditary brain tumor syndromes in particular, neurofibromatosis 1, neurofibromatosis 2, schwannomatosis, and tuberous sclerosis; and comparative pathology with genetically modified mouse models.

Edit Profile

Research & Publications

Research Summary

Our lab's research focuses on identifying the underlying molecular changes in the lesions and malformations associated with hereditary brain tumor syndromes (neurofibromatosis 1, neurofibromatosis 2, schwannomatosis and tuberous sclerosis), and the identification of activated pathways or events that lead to tumor progression. We are now moving from defining the molecular features and understanding the biology to more practical translational research of biomarkers and drug screens.

See details at the Stemmer-Rachamimov Lab.


View my most recent publications at PubMed

  1. Failure to Detect Human Papillomavirus in Focal Cortical Dysplasia Type IIb.
    Shapiro KA, McGuone D, Deshpande V, Sadow PM, Stemmer-RachamimovA, Staley KJ. Ann Neurol. 2015 Apr 20.[Epub ahead of print]
  2. Sporadic hemangioblastomas are characterized by cryptic VHL inactivation. Shankar GM, Taylor-Weiner A, Lelic N, Jones RT, Kim JC, Francis JM, Abedalthagafi M, Borges LF, Coumans JV, Curry WT, Nahed BV, Shin JH, Paek SH, Park SH, Stewart C, Lawrence MS, Cibulskis K, Thorner AR, Van Hummelen P, Stemmer-Rachamimov AO, Batchelor TT, Carter SL, Hoang MP, Santagata S, Louis DN, Barker FG, Meyerson M, Getz G, Brastianos PK, Cahill DP. Acta Neuropathol Commun. 2014 Dec 24;2:167.
  3. Phase 2 study of bosutinib, a Src inhibitor, in adults with recurrent glioblastoma. Taylor JW, Dietrich J, Gerstner ER, Norden AD, Rinne ML, Cahill DP,Stemmer-Rachamimov A, Wen PY, Betensky RA, Giorgio DH, Snodgrass K, Randall AE, Batchelor TT, Chi AS. J Neurooncol. 2015 Feb;121(3):557-63. doi: 10.1007/s11060-014-1667-z. Epub 2014 Nov 20.

Edit Profile


Pathology Associates
55 Fruit Street
Boston MA, 02114-2696
Phone: 617-726-5510617-726-5156
Fax: 617-724-1813

Edit Profile

Back to Top